Literature DB >> 9418630

Cost effectiveness and quality of life in knee arthroplasty.

C J Lavernia1, J F Guzman, A Gachupin-Garcia.   

Abstract

Few studies quantitate the cost of a quality well being as produced by arthroplasty surgery. The objective was to use the Quality of Well Being Index to calculate the cost per quality of well year in knee arthroplasty surgery. The difference in Quality of Well Being Index scores before and after the intervention was calculated and multiplied by the patient's life expectancy. The procedure cost was divided by this quantity resulting in the cost of a quality well year. One hundred patients underwent a primary knee arthroplasty. There were 30 males (average age, 62 years old) and 70 females (average age, 64 years old). The calculated costs per a quality well year were $30,695 (standard deviation $90,883) at 3 months, $17,804 (standard deviation $25,888) at 6 months, $11,560 (standard deviation $11,874) at 1 year, and $6656 (standard deviation $3567) at 2 years postsurgery. Health economists consider an intervention costing less than $30,000 per quality of well year a bargain to society. Cost effectiveness of knee arthroplasty surgery compares favorably with other surgical interventions such as coronary artery bypass surgery ($5000 per quality of well year) and extremely favorable with medical treatments such as renal dialysis ($50,000.00 for the quality well year). Knee arthroplasty is a cost effective procedure and should be considered an appropriate investment by society.

Entities:  

Mesh:

Year:  1997        PMID: 9418630

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  50 in total

1.  Patient vs provider characteristics impacting hospital lengths of stay after total knee or hip arthroplasty.

Authors:  Joseph F Styron; Siran M Koroukian; Alison K Klika; Wael K Barsoum
Journal:  J Arthroplasty       Date:  2011-01-28       Impact factor: 4.757

Review 2.  Methods for measuring temporary health States for cost-utility analyses.

Authors:  Davene R Wright; Eve Wittenberg; J Shannon Swan; Rebecca A Miksad; Lisa A Prosser
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

3.  Reducing periprosthetic joint infection: what really counts?

Authors:  Giuseppe Solarino; Antonella Abate; Giovanni Vicenti; Antonio Spinarelli; Andrea Piazzolla; Biagio Moretti
Journal:  Joints       Date:  2016-01-31

Review 4.  Complications for racial and ethnic minority groups after total hip and knee replacement: a review of the literature.

Authors:  Benedict U Nwachukwu; Adrian D Kenny; Elena Losina; Lori B Chibnik; Jeffrey N Katz
Journal:  J Bone Joint Surg Am       Date:  2010-02       Impact factor: 5.284

5.  Defining racial and ethnic disparities in THA and TKA.

Authors:  Kaan Irgit; Charles L Nelson
Journal:  Clin Orthop Relat Res       Date:  2011-07       Impact factor: 4.176

6.  [Long-term results in total knee arthroplasty. A meta-analysis of revision rates and functional outcome].

Authors:  J Lützner; U Hübel; S Kirschner; K-P Günther; F Krummenauer
Journal:  Chirurg       Date:  2011-07       Impact factor: 0.955

7.  Assessing the value of a total joint replacement.

Authors:  David B Bumpass; Ryan M Nunley
Journal:  Curr Rev Musculoskelet Med       Date:  2012-12

8.  Outcome analysis of hip or knee arthroplasty in patients with cirrhotic liver disease.

Authors:  Young-Jun Seol; Taek-Rim Yoon; Dong-Hyun Lee; Sun-Ho Lee; Kyung-Soon Park
Journal:  J Orthop       Date:  2017-01-04

9.  The influence of income and race on total knee arthroplasty in the United States.

Authors:  Jonathan Skinner; Weiping Zhou; James Weinstein
Journal:  J Bone Joint Surg Am       Date:  2006-10       Impact factor: 5.284

10.  Two-stage revision for prosthetic joint infection: predictors of outcome and the role of reimplantation microbiology.

Authors:  P Bejon; A Berendt; B L Atkins; N Green; H Parry; S Masters; P McLardy-Smith; R Gundle; I Byren
Journal:  J Antimicrob Chemother       Date:  2010-01-06       Impact factor: 5.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.